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The reactive advanced glycation end product (AGE) precur-
sor methylglyoxal (MGO) and MGO-derived AGEs are associ-
ated with diabetic vascular complications and also with an in-
crease in oxidative stress. Glyoxalase-I (GLO-I) transgenic rats
were used to explore whether overexpression of this MGO de-
toxifying enzyme reduces levels of AGEs and oxidative stress
in a rat model of diabetes. Rats were made diabetic with strep-
tozotocin, and after 12 weeks, plasma and multiple tissues
were isolated for analysis of AGEs, carbonyl stress, and oxida-
tive stress. GLO-I activity was significantly elevated in multiple
tissues of all transgenic rats compared with wild-type (WT)
littermates. Streptozotocin treatment resulted in a 5-fold in-
crease in blood glucose concentrations irrespective of GLO-I
overexpression. Levels of MGO, glyoxal, 3-deoxyglucosone,
AGEs, and oxidative stress markers nitrotyrosine, malondial-
dehyde, and F2-isoprostane were elevated in the diabetic WT
rats. In diabetic GLO-I rats, glyoxal and MGO composite
scores were significantly decreased by 81%, and plasma AGEs
and oxidative stress markers scores were significantly de-
creased by50%. Hyperglycemia induced a decrease in pro-
tein levels of the mitochondrial oxidative phosphorylation
complex in the gastrocnemius muscle, which was accompanied
by an increase in the lipid peroxidation product 4-hydroxy-2-
nonenal, and this was counteracted by GLO-I overexpression.
This study shows for the first time in an in vivo model of dia-
betes that GLO-I overexpression reduces hyperglycemia-in-
duced levels of carbonyl stress, AGEs, and oxidative stress. The
reduction of oxidative stress by GLO-I overexpression directly
demonstrates the link between glycation and oxidative stress.
Prolonged exposure to hyperglycemia has detrimental ef-
fects on various cellular functions and is believed to be the
most important factor in the development of vascular compli-
cations in diabetes. One of the hypotheses about how hyper-
glycemia leads to complications is the formation of advanced
glycation end products (AGEs)3 (1). In addition to the forma-
tion of AGEs by the classical Maillard reaction (2, 3), dicar-
bonyls such as methylglyoxal (MGO), glyoxal (GO), and 3-de-
oxyglucocone (3-DG) are also known to form AGEs. MGO is
probably the most important precursor in this formation of
AGEs (4). This highly reactive oxo-aldehyde is formed mainly
by the non-enzymatic and enzymatic fragmentation of the
triose phosphates glyceraldehyde 3-phosphate and dihydroxy-
acetone phosphate. MGO reacts primarily with arginine resi-
dues to form the major AGEs, hydroimidazolone (MG-H1),
argpyrimidine (AP) and tetrahydropyrimidine (THP), and
with lysine residues to minor AGEs such as N-(1-carboxy-
ethyl)lysine (CEL). MGO is efficiently detoxified by the glyox-
alase system. In this pathway MGO reacts with reduced gluta-
thione (GSH) to a hemithioacetal adduct and then to S-D-
lactoyl-glutathione, which is catalyzed by glyoxalase-I (GLO-
I). This product is converted into D-lactate by glyoxalase-II,
thereby reforming the consumed GSH. A similar reaction
with glyoxal can take place via the intermediate S-glycolyl-
glutathione (5). Overexpression of GLO-I prevents the accu-
mulation of MGO and AGEs in endothelial cells exposed to
high glucose concentration in vitro, indicating that GLO-I
plays an important role in the suppression of AGE formation
under hyperglycemic condition (6).
Among other adverse effects, MGO induces dysfunction of
mitochondrial respiration (7) and increases the production of
reactive oxygen species (ROS) (8, 9). Also, the decrease of
GLO-I activity by an inhibitor results in altered cellular func-
tion (10–12). Recently Schlotterer et al. (13) showed that
GLO-I overexpression in Caenorhabditis elegans decreased
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hyperglycemia-induced accumulation of AGEs and oxidative
stress and enhanced lifespan.
Nevertheless, in higher organisms the in vivo effect of
GLO-I overexpression on hyperglycemia induced AGE forma-
tion, and ROS production has not yet been studied. There-
fore, in this study we investigated the phenotype of diabetic
transgenic rats with a GLO-I overexpression. We hypothe-
sized that these rats will have less MGO and MGO-derived
adducts in comparison with their wild-type diabetic litter-
mates and that this would have beneficial effects on the for-
mation of hyperglycemia-induced ROS production.
EXPERIMENTAL PROCEDURES
Glyoxalase-I Transgenic Rats—To generate the human
GLO-I transgene construct, the entire coding sequence of
human GLO-I cDNA was cloned into the EcoRI site of the
pBsCAG-2. The GLO-I transgene, isolated by digestion of
pBsCAG-2 containing GLO-I cDNA with KpnI and SacI, was
microinjected into one pronucleus of fertilized Wistar eggs
followed by transfer into the oviducts of pseudopregnant rats.
The procedure used was comparable with the generation of
glyoxalase-I-overexpressing mice (14). Rat genomic DNA ex-
tracted from tail tissue was used to detect the transgene by
PCR using specific primers for GLO-I or pBsCAG-2 vector.
Primers for cytomegalovirus enhancer sense (5-GTC GAC
ATT GAT TAT TGA CTA G-3) and antisense (5-CCA
TAA GGT CAT GTA CTG-3) amplified a 350-bp fragment.
Primers for the fragment containing human GLO-I gene and
3 junction of vector, sense (5-GTA GTG TGG GTG ACT
CCT CCG TTC CTT GGG-3) and antisense (5-TCG AGG
GAT CTT CAT AAG AGA AGA G-3), amplified a 1200-bp
fragment. PCR amplification was carried out with an initial
denaturation at 94 °C for 2 min followed by 35 cycles of 95 °C
for 30 s, 55 or 58 °C for 30 s, and 72 °C for 30 or 75 s.
Induction of Diabetes with Streptozotocin—All animal stud-
ies were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. All experiments involving rats were reviewed and ap-
proved by the ethics committee for animal care and use of the
Maastricht University, The Netherlands.
Wild-type rats (WtD, n 9) and transgenic GLO-I rats
(TgD, n 8) were made diabetic by intravenous injection of
streptozotocin (65 mg/kg of body weight). Weight- and age-
matched control rats (WtC, n 9) and transgenic GLO-I rats
(TgC, n 8) were not injected. Blood glucose levels were
monitored at base line and after 1 and 12 weeks. Only strepto-
zotocin-injected rats with a fasting blood glucose level above
15 mM after 1 and 12 weeks were included in the study as dia-
betic. Body weight, food and fluid intake, urine production,
and urinary creatinine levels were measured at base line and
after 12 weeks. Three months after the induction of diabetes,
rats were sacrificed, and multiple tissues were processed for
analysis. Samples from various organs were fixed in 4% neu-
tral-buffered formaldehyde, embedded in paraffin, and sec-
tioned at 4-m thickness. Blood samples were collected at the
time of sacrifice for hematological and biochemical analyses.
Tissues (50 mg) from wild-type or GLO-I transgenic rats were
homogenized in 1 ml of 0.1 M sodium phosphate buffer, pH
7.0, containing 0.02% Triton X-100 and centrifuged at
20,000 g for 20 min at 4 °C. The supernatant was used as a
tissue lysate to assess GLO-I protein expression with Western
blotting and GLO-I activity.
Glyoxalase-I Activity Measurement—GLO-I activity was
assayed by spectrophotometry by monitoring the increase in
absorbance at 240 nm due to the formation of S-D-lactoyl-
glutathione for 10 min at 37 °C according to the method by
McLellan et al. (15).
Preparation of Anti-MGO Antibodies—MGO keyhole lim-
pet hemocyanin (KLH) was prepared by the reaction of MGO
(10 mM) with KLH for 7 days at 37 °C and was used as the an-
tigen for the immunization of mice. MGO-KLH was emulsi-
fied in an equal volume of Freund’s complete adjuvant, and
three mice were intradermally injected at multiple sites. The
mice were boosted with the same amount of MGO-KLH
emulsified in Freund’s incomplete adjuvant 21 days later, and
antisera were obtained 14 days after the booster were tested.
The booster was repeated twice. Ten days after the final
booster, antisera were tested with MGO-albumin, and the
mouse with the highest titer was used for fusion. We obtained
40 positive clones as tested with MGO-albumin, and one of
them was further characterized. This monoclonal antibody
was from the IgG1 subclass and has an at least 1000-fold pref-
erence for tetrahydropyrimidine (THP) as compared with
argpyrimidine (AP) or 5-hydro-5-methyl-4-imidazolone
(MG-H1).
Preparation of MGO-albumin—Human serum albumin (6.8
mg) was dialyzed against phosphate buffer (0.1 M) and fil-
trated through a 0.45-m filter followed by incubation in a
phosphate buffer (0.2 M), pH 7.8, with different concentra-
tions of MGO (0.5–10 mM).
MGO-albumin ELISA—In a competitive ELISA performed
at room temperature, each well was coated with 100 l of 0.1
mg/ml MGO-albumin, as prepared by the incubation of albu-
min with 0.5 mM MGO for 2 days in PBS for 1 h at room tem-
perature or overnight at 4 °C. This MGO-albumin prepara-
tion was also used as standard in the competitive ELISA. To
each well 50 l of the antibody (anti-THP (1:2,000) or anti-
MG-H1 (1:100,000) and 50 l of standard or plasma sample
to be tested were added. After incubation for 1 h and 3 washes
with PBS-Tween, the wells were incubated with 100 l of per-
oxidase-labeled goat-anti-mouse (1:5000, Dako, Glostrup,
Denmark) for 1 h. Finally, the wells were washed 5 times with
PBS-Tween, and the substrate was developed with 100 l of
tetramethylbenzidine. The reaction was stopped with 100 l
of 0.5 M H2SO4. The extinction at 450 nm was measured with
a multichannel spectrophotometer (SLT Microplate reader,
Wilten Bioteknika, Etten-Leur, The Netherlands). Plasma
levels were expressed as arbitrary units, and 1 unit was de-
fined as the antibody-reactive material equivalent to 1 g of
the MGO-albumin standard.
Measurement of Oxo-aldehydes and AGEs—Blood samples
were collected in 0.8 M perchloric acid, and concentrations of
the dicarbonyls MGO and GO were determined by reversed-
phase high performance liquid chromatography (HPLC) with
fluorescence detection after derivatization to their respective
dimethoxyquinoxaline derivatives (16). Concentrations of the
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dicarbonyl 3-DG were measured with HPLC tandem mass
spectrometry after derivatization with dinitrophenylhydrazine
(17).
In addition, protein-bound N-(1-carboxy-methyl)lysine
(CML) and CEL were measured in plasma by HPLC tandem
mass spectrometry (18). Protein-bound argpyrimidine was
measured by HPLC with fluorescent detection with the same
sample preparation as described by Scheijen et al. (19) for
pentosidine.
Measurement of D-Lactate and Markers of Oxidative
Stress—D-Lactate was measured in blood and urine by an en-
zymatic assay with spectrophotometric quantification (20).
8-Isoprostane (21) and malondialdehyde (MDA) (22) levels
were measured in rat urine by HPLC with MS-MS or fluores-
cence detection, respectively.
Western Blot Analysis of Mitochondrial Proteins and Oxida-
tive Stress Markers—Western blot analyses were performed in
muscle homogenates of the gastrocnemius muscle using an
antibody mixture (MS601; MitoSciences, Eugene, OR) against
structural components of four of the five oxidative phospho-
rylation complexes (i.e. to the ND6 subunit of complex I, the
30-kDa Ip subunit of complex II, the 47-kDa core protein 2 of
complex III, and the -subunit of the F1F0 ATP synthase of
complex V).
In the whole muscle homogenates, we also analyzed uncou-
pling protein-3, adenine nucleotide translocase 1 (MSA02;
MitoSciences), and 4-hydroxy-2-nonenal (4-HNE) (JAICA,
Fukuroi, Japan) protein content by Western blotting accord-
ing to Hoeks et al. (23). The nitric oxide oxidation product,
peroxynitrite (polyclonal nitrotyrosine antibody from, Calbio-
chem), was detected in kidney lysates. In brief, upon homoge-
nization in lysis buffer containing 1% Nonidet P-40, 0.5% so-
dium dodecyl sulfate, 1 mmol/l phenylmethylsulfonyl
fluoride, and 4% complete inhibitor mixture, lysates were pro-
cessed for Western blotting. After incubation with the appro-
priate secondary antibodies, protein-specific bands were de-
tected and quantified with the Odyssey Infrared Imager (LI-
COR; Westburg, Leusden, The Netherlands) or the Chemidoc
Imager (Bio-Rad) and expressed as -fold change to the wild-
type control group.
Statistical Analysis—Differences between groups in levels
of each marker examined were tested using one-way analysis
of variance. Post-hoc Bonferroni correction was used for the
comparison of the three groups of interest (WtC versusWtD,
WtD versus TgD, and WtC versus TgD). We also calculated
and compared between groups a composite score of GLO-I-
sensitive oxo-aldehydes (CO and MGO), GO- and MGO-de-
rived AGEs (CML, CEL, MH-H1, THP, and AP), and ROS
(MDA, 8-isoprostane, and nitrotyrosine) by averaging the
z-scores of each of the respective markers. Each z-score rep-
resents the distance between the raw score from the total
mean in units of the S.D. (assuming negative values when the
raw score is below the mean and positive when above), thus,
enabling the combination of several markers originally ex-
pressed as different units. The three composite scores thus
obtained represent a good integral measure of the processes/
mechanisms they represent and have the advantage of reduc-
ing the influence of the biological variability when each of
their constituent markers is tested separately. To enable a
meaningful interpretation of the magnitude of the differences
in these composite scores, comparisons between the Tg dia-
betic group and the referent group (WT) were also expressed
relative to the levels in this group (i.e. as percentage). A p
value of less than 0.05 was considered statistically significant.
Data are expressed as the mean S.E.
RESULTS
Glyoxalase-I Overexpression in the Transgenic GLO-I
Rats—GLO-I activity was significantly elevated in multiple
tissues of the GLO-I transgenic rats including heart, kidney,
eye, brain, aorta, and gastrocnemius muscle as compared with
their WT littermates (Fig. 1A). In these tissues human GLO-I
protein expression was confirmed by immunoblotting and by
immunohistochemical staining as shown for the heart and
kidney (Fig. 1, B and C). These data demonstrated a function-
ally active overexpression of GLO-I in the GLO-I transgenic
rats.
Base-line and End Point Characteristics—Table 1 presents
biochemical data and characteristics of both the non-diabetic
and diabetic WT and GLO-I transgenic rats. Diabetes in both
WT and GLO-I transgenic rats, as induced by streptozotocin,
resulted in an5-fold increase in blood glucose levels, de-
FIGURE 1.GLO-I activity and human protein expression in tissue of wild-
type and transgenic GLO-I rats. A, shown is GLO-I enzyme activity (act.) in
lysates of heart, kidney, eye, brain, aorta, and gastrocnemius muscle tissue
of WtC, TgC, WtD, and TgD rats. B, shown is a Western blot of human GLO-I
protein overexpression in transgenic heart and kidney compared with wild-
type heart and kidney lysates. C, immunohistochemistry of GLO-I protein
overexpression in transgenic heart (C2) and kidney (C4) compared with
wild-type (C1, C3) is shown. **, p 0.01 compared with control; ***, p
0.001 compared with control.
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creased weight gain, and increased food and fluid intake and
urine production without a difference between the WT and
the GLO-I transgenic rats.
GLO-1 Overexpression Reduces Elevated Levels of MGO and
GO in Diabetic Rats—The AGE precursors, MGO, GO, and
3-DG, were significantly elevated in the diabetic WT rats as
compared with non-diabetic WT rats (Fig. 2, A–C). Levels of
the GLO-I-sensitive GO and MGO were normalized in the
GLO-I transgenic diabetic rats compared with the WT rats,
whereas 3-DG levels were not influenced by the GLO-I over-
expression. The composite score of MGO and GO differed
between the WT diabetic and transgenic diabetic group by
1.04. This difference corresponds to a significant 81% de-
crease in the composite score of GO and MGO in the GLO-I
transgenic diabetic rats compared with the WT diabetic rats
(p 0.05; Fig. 2D).
In addition, the end product of the GLO system, i.e. D-lac-
tate, was determined. The plasma levels of D-lactate were ele-
vated in the diabetic rats compared with the non-diabetic rats
(Fig. 2E). Also, the urine samples showed an increase of D-
lactate in the diabetic rats, with a higher concentration of D-
lactate in the diabetic GLO-I transgenic rats, indicating a high
flux of MGO through the GLO-I pathway (Fig. 2F).
GLO-1 Overexpression Reduces Elevated Levels of AGEs in
Diabetic Rats—Next, we evaluated if the overexpression of
GLO-I also led to a decreased formation of AGEs. We mea-
sured protein-bound levels of CML, CEL, MG-H1, THP, and
AP in the plasma of the four groups. All AGE adducts were
elevated in the plasma of diabetic WT rats compared with
non-diabetic WT rats, and this was statistically significant for
CML, MG-H1, and AP. There was a trend that the diabetes-
induced increase of all AGEs was partially reduced in the dia-
betic GLO-I transgenic rats as compared with the diabetic
WT rats (Fig. 3, A–E), although the reduction of the individ-
ual AGEs did not reach statistical significance. The absolute
FIGURE 2.Oxo-aldehyde formation and detoxification of (M)GO in the
blood of wild-type and transgenic GLO-I rats. Glyoxal (A), MGO (B), and
3-DG (C) levels in the blood of WtC, TgC, WtD, and TgD rats are shown. A
composite score was calculated for the GLO-I- sensitive oxo-aldehydes GO
and MGO (D). D-Lactate levels in the plasma (E) and urine (F) of the WtC,
TgC, WtD, and TgD rats are shown. *, p 0.05 compared with control; **,
p 0.01 compared with control; ***, p 0.001 compared with control; #,
p 0.05 compared with wild-type diabetic.
FIGURE 3. Formation of AGEsmeasured in plasma fromwild-type and
transgenic GLO-I rats. CML (A), CEL (B), MG-H1 (C), THP (D), and AP (E) lev-
els were measured with HPLC-MS/MS and competitive ELISA in the plasma
of the WtC, TgC, WtD, and TgD rats. In addition a composite score was cal-
culated for the five AGEs (F). *, p 0.05 compared with control; ***, p
0.001 compared with control; #, p 0.05 compared with wild-type diabetic
TABLE 1
Base-line and end point characteristics of the wild-type control, GLO-I control, wild-type diabetic, and GLO-I diabetic rats
BL, base line; EP, endpoint.
Parameters
Wild-type control GLO-I control Wild-type diabetic GLO-I diabetic
Male Female Male Female Male Female Male Female
Glucose (mM)
BL 3.9 0.5 3.9 0.3 3.8 0.4 3.9 0.4 3.9 0.2 3.8 0.3 4.0 0.4 4.0 0.2
EP 4.9 1.2 4.5 0.7 4.3 0.6 3.8 0.5 20.2 2.1a,b 20.3 3.0a,b 19.2 1.5a,b 21.9 4.3a,b
Weight (g)
BL 308 35 198 29 327 40 205 20 341 35 203 17 310 27 195 24
EP 475 15a 256 9a 486 15a 260 13a 318 48b 216 32 318 23b 212 8b
Food (g)
BL 29 0.9 23 7.4 26 5.3 17 4.4 27 2.4 17 1.8 25 4.0 18 3.0
EP 20 3.8 20 3.0 18 1.7 23 2.0 47 6.3a,b 35 8.1a,b 48 5.1a,b 40 3.5 a,b
Fluid (ml)
BL 32 4.6 27 9.9 30 5.2 27 2.8 36 2.7 24 1.8 35 4.9 25 2.0
EP 27 6.1 28 4.7 27 3.5 30 8.0 169 21.4a,b 196 57.7a,b 246 66.9a,b 163 12.8a,b
Urine (ml)
BL 12 1.3 10 1.9 13 3.9 11 1.3 13 1.1 11 1.0 11 1.1 9 2.3
EP 19 4.4 18 2.1 20 7.6 24 14.2 165 24.9a,b 176 104.7a,b 205 19.6a,b 114 35.3a,b
a p 0.05 compared with base line.
b p 0.05 compared with control.
GLO-I Overexpression in Diabetic Rats
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difference in the overall composite protein-bound AGEs score
in the plasma of WT diabetic rats versus the transgenic dia-
betic rats was 0.73, and this corresponds to a significant 54%
reduction in the composite score of plasma AGEs in diabetic
GLO-I transgenic rats compared with the diabetic WT rats
(p 0.05; Fig. 3F).
GLO-1 Overexpression Reduces Elevated Oxidative Stress
Markers in Urine and Tissue in Diabetic Rats—Furthermore,
we examined the effect of GLO-I overexpression on oxidative
stress. The urinary excretion of MDA and 8-isoprostane were
significantly increased in the diabetic WT rats after 12 weeks
of diabetes (Fig. 4, A and B). This increase in estimates of oxi-
dative stress was partially prevented in the diabetic GLO-I
transgenic rats, although it did not reach statistically signifi-
cance. In addition, kidney tissue levels of the peroxynitrite
marker nitrotyrosine were elevated in the diabetic WT rats
and significantly (p 0.05) attenuated in the diabetic GLO-I
transgenic rats (Fig. 4C). The difference in the composite
score of these oxidative stress markers between the WT dia-
betic rats and the transgenic diabetic rats was 0.84, which cor-
responds to a significant 51% decrease in the composite ROS
score in the diabetic GLO-I transgenic rats as compared with
the diabetic control rats (p 0.05; Fig. 4D).
Protein Levels of Mitochondrial Oxidative Phosphorylation
Complexes—To gain more information about the source of
the oxidative stress, we measured the levels of four structural
proteins of the complexes of the mitochondrial respiration
chain. Complex I, II, III, and V of the mitochondrial respira-
tion chain in gastrocnemius muscle lysates were all signifi-
cantly decreased in the wild-type diabetic rats. In the trans-
genic diabetic rats this decrease was partially counteracted by
the GLO-I overexpression. The mitochondrial proteins ade-
nine nucleotide translocator-1 and uncoupling protein-3 were
not altered by diabetes or GLO-I overexpression, indicating a
specific effect on the oxidative phosphorylation complexes
(see Fig. 5, A–F). The decrease in phosphorylation complexes
was accompanied by an increase in the lipid oxidation marker
4-HNE in the muscle from the wild-type diabetic rats (Fig.
5G), which was normalized by GLO-I overexpression.
DISCUSSION
We report here that GLO-I overexpression in diabetic rats
prevents the hyperglycemia-induced formation of MGO, GO,
and AGEs, as well as oxidative stress in diabetes. To demon-
strate the importance of GLO-I in the formation of AGEs,
transgenic GLO-I rats were generated and increased GLO-I
protein levels, and activity was confirmed by Western blot-
ting, Immunohistochemistry, and enzyme activity measure-
ments, respectively. The GLO-I activity was at least 10–50-
fold higher in GLO-I transgenic rats compared with WT rats
FIGURE 4. Formation of ROSmarkers in urine and tissue fromwild-type
and transgenic GLO-I rats.MDA (A), 8-isoprostane (B), and kidney nitroty-
rosine (C) levels in WtC, TgC, WtD, and TgD rats were measured with HPLC
and Western blotting, and a composite score was calculated for the three
ROS markers (D). * p 0.05 compared with control; **, p 0.01 compared
with control; ***, p 0.001 compared with control; # p 0.05 compared
with wild-type diabetic. A.U., absorbance units. Creat, creatinine.
FIGURE 5. Protein levels of mitochondrial proteins and formation of
4-HNE in themuscle of wild-type and transgenic GLO-I rats. The mito-
chondrial proteins Complex I (A), II (B), III (C), V (D), ANT (E), uncoupling pro-
tein-3 (UCP-3) (F), and lipid oxidation marker 4-HNE (G) were measured by
Western blotting in gastrocnemius muscle lysates of the WtC, TgC, WtD,
and TgD rats. *, p 0.05 compared with control; **, p 0.01 compared
with control; ##, p 0.01 compared with wild-type diabetic. A.U., absorb-
ance units.
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in several highly vascularized tissues i.e. heart, kidney, eye,
brain, aorta, and gastrocnemius muscle.
Our findings are consistent with previous reports. Shino-
hara et al. (6) transfected endothelial cells with GLO-I, and
the hyperglycemia-induced formation of MGO could be com-
pletely normalized by the overexpression of GLO-I, resulting
in lower intracellular MGO-derived AGE formation but not
of CML and CEL. Consistently, Miyata et al. (24) demon-
strated that a deficiency of GLO-I is associated with increased
levels of AGEs, further underlining the importance of glyox-
alase detoxification system, in particular GLO-I, for the actual
level of AGEs.
In our study, diabetes, as induced by streptozotocin treat-
ment, resulted in increased MGO, GO, and 3-DG levels. The
fact that in our study only the GLO-I substrates MGO and
GO are reduced by GLO-I and not 3-DG, which cannot be
degraded by GLO-I, underlines the specificity of the GLO-I
transgenic model. In addition to a decrease of MGO and GO,
we found that the MGO- and/or GO-derived AGEs, MG-H1,
THP, AP, CML, and CEL were decreased in the plasma of the
diabetic GLO-I-overexpressing model as compared with WT
diabetic rats. Despite the trend toward reduction in all mark-
ers, this decrease was only statistically significant when all
these markers were combined into a more robust overall
score of AGEs. Therefore, interpretations about the effect of
GLO-I overexpression on each of the separate AGE adducts
should be taken with care. Furthermore, the composite score
decrease in total AGE levels was on average only 54% despite
the 81% reduction of GO and MGO. This only partial reduc-
tion in the formation of AGEs in the diabetic transgenic rats
might be due to alternative pathways in the formation of
AGEs independent of the precursors MGO and GO and inde-
pendent of GLO-I expression. Because the glucose levels were
elevated 5-fold in the diabetic rats compared with controls,
with no effect of GLO-I overexpression, it might be that a
significant part of the formation of AGEs is formed via the
classical Maillard reaction. In addition, some AGEs, such as
CML, can also be formed directly by lipid oxidation and via
the myeloperoxidase reaction, which can explain the GLO-I
independent formation of AGEs in diabetes (25).
In addition to the effect on carbonyl stress and AGEs,
GLO-I overexpressing also reduced hyperglycemia-evoked
ROS generation, as estimated by three markers of oxidative
stress, i.e. 8-isoprostane, MDA, and nitrotyrosine. 8-Isopros-
tane is a prostaglandin-like compound generated in vivo by
the free-radical-catalyzed peroxidation of arachidonic acid
(26). MDA is a bioactive aldehyde generated by extensive oxi-
dation of polyunsaturated fatty acids (27), and nitrotyrosine is
formed when the oxidant product of nitric oxide, peroxyni-
trite, nitrosates tyrosine. Our study shows that these markers
of oxidative stress are increased in diabetes and that GLO-I
overexpression is capable of lowering these three markers of
oxidative stress. These data strongly indicate that MGO plays
a relevant role in modulating diabetes-induced ROS produc-
tion, which is in agreement with earlier studies with amin-
oguanidine and aldose reductase inhibitors (28–30).
Oxidative stress contributes significantly to the develop-
ment and progression of diabetes and related vascular compli-
cations (31). The main source of ROS in diabetes is most
probably due to altered mitochondrial metabolism, which
results in overproduction of superoxide by the electron trans-
port chain (32). Rosca et al. (9) described that several mito-
chondrial proteins are susceptible to MGO-dependent glyca-
tion, and consequently excessive superoxide is produced due
to a decreased electron transport chain activity. In accordance
with this study, hyperglycemia also leads to mitochondrial
glycation in C. elegans (13), which was decreased by overex-
pression of GLO-I, indicating the importance of glyoxalase
sensitive oxo-aldehydes in the formation of oxidative stress.
To further explore the potential source of the oxidative stress
in our model, we determined the protein levels of four struc-
tural proteins of the mitochondrial electron transport chain
complexes. All these complexes were decreased in the dia-
betic rats and increased by GLO-1 overexpression. This de-
crease in electron transport chain proteins could lead to defi-
cient mitochondrial function and structure and may
contribute to the abnormality of energy metabolism. A conse-
quence of defective mitochondrial function is the increased
generation of free radicals, which are normally produced as
byproducts of oxidative metabolism (33). These free radicals
are able to oxidize lipids, proteins, nucleic acids, and other
molecules, altering their structure and function (34). Indeed,
lipid peroxidation was also measured in the muscle of our
diabetic rats by the elevation of the oxidative stress marker
4-HNE. In the GLO-1 overexpression diabetic rat lipid per-
oxidation was completely prevented, paralleled by an increase
in markers of mitochondrial function, suggesting that MGO
may affect mitochondrial ROS production via an effect on
mitochondrial function.
Pharmaceutical quenching of MGO in vivo is frequently
used in the prevention of diabetic complications in animal
models. MGO can be trapped by guanidine compounds such
as aminoguanidine and metformin and by vitamin B analogs
like pyridoxamine and can be reduced by the activation of
transketolase by thiamine and benfothiamine. Indeed, these
compounds lower MGO levels (35). However, because these
guanidine compounds are far from specific, the precise con-
tribution of MGO and GO in diabetic complications is still
largely unknown. Therefore, this new transgenic rat model,
which specifically decreases GLO-I-sensitive aldehydes such
as MGO and GO and their derived AGEs, can provide impor-
tant knowledge about the contribution of GO, MGO, and
(M)GO-derived AGEs in the development of diabetic (vascu-
lar) complications. Indeed, we recently demonstrated in this
model that hyperglycemia-induced impairment of endotheli-
um-dependent vasorelaxation in mesenteric arteries is medi-
ated by intracellular MGO levels (36), demonstrating the use-
fulness of this model.
In conclusion, our study shows for the first time that GLO-I
overexpression decreased GO, MGO, AGEs, and ROS levels
under in vivo hyperglycemic conditions. These data are con-
sistent with the link between glycation and oxidative stress.
Excessive formation of AGEs and oxidative stress has been
implicated in the development of vascular complications in
diabetes, and therefore, activation of the GLO-I pathway
GLO-I Overexpression in Diabetic Rats
JANUARY 14, 2011•VOLUME 286•NUMBER 2 JOURNAL OF BIOLOGICAL CHEMISTRY 1379
 at VR
IJE UNIVERSITEIT, on February 6, 2013
w
w
w
.jbc.org
D
ow
nloaded from
 
could be an important target in the prevention of diabetes-
induced vascular damage.
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